Market Research Logo

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2016

Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2016’, provides an overview of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)
  • The report reviews pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) therapeutics and enlists all their major and minor projects
  • The report assesses Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) Overview
Therapeutics Development
Pipeline Products for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Overview
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Therapeutics under Development by Companies
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Products under Development by Companies
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Companies Involved in Therapeutics Development
Achillion Pharmaceuticals, Inc.
Akari Therapeutics, Plc
Alexion Pharmaceuticals, Inc.
Amgen Inc.
ChemoCentryx, Inc.
Epirus Biopharmaceuticals, Inc.
greenovation Biotech GmbH
Kedrion S.p.A.
Omeros Corporation
Ra Pharmaceuticals, Inc.
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACH-4471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALXN-1210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCX-168 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Coversin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRN-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-721 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein for Atypical Hemolytic Uremic Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RA-101495 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Complement Factor D for Acute Hemolytic Uremic Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Dormant Projects
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Product Development Milestones
Featured News & Press Releases
May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress
May 09, 2016: EPIRUS Announces Reprioritization of Pipeline, to focus on biosimilar product BOW080
Mar 08, 2016: Omeros Initiates its Phase 3 Program for OMS721 in aHUS Following Meeting with FDA
Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial
Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays
Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting
Dec 05, 2015: Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
Aug 18, 2015: Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial
Jul 23, 2015: FDA Grants Fast Track to Omeros' Complement Inhibitor OMS721 for aHUS
Apr 14, 2015: European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721
Mar 31, 2015: Greenovation And University Of Freiburg Cooperate To Fight An Extremely Rare Disease
Nov 20, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in Atypical Hemolytic Uremic Syndrome Treatment by the FDA
Nov 19, 2014: OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients
Apr 03, 2014: Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies
Mar 10, 2014: Omeros Announces Positive OMS721 Data in Serum from Patients with aHUS
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Akari Therapeutics, Plc, H2 2016
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Alexion Pharmaceuticals, Inc., H2 2016
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Amgen Inc., H2 2016
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by ChemoCentryx, Inc., H2 2016
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by greenovation Biotech GmbH, H2 2016
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Kedrion S.p.A., H2 2016
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Omeros Corporation, H2 2016
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Pipeline by Ra Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome) - Dormant Projects, H2 2016
List of Figures
Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report